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Background: Single lung transplant recipients with idiopathic pulmonary fibrosis provide
an opportunity to study fibrosis in the native lung over time in the setting of pronounced
immunosuppression. Lung transplant patients are treated with a regimen of steroids, an anti-
proliferative agent and a calcineurin inhibitor. This represents a much greater immunosuppres-
sion regime than the typical treatment for IPF. To determine whether this regimen of high dose
immunosuppression would arrest the progression of fibrosis, the high-resolution chest CT scans
(HRCTs) of these patients were reviewed.
Methods: HRCTs of 21 patients who underwent single lung transplant for IPF between 1/96 and
1/06 were reviewed. Scans were evaluated by two readers at 6 months intervals, beginning
within 1e2 months after transplant. Two calculations were made on the native lung: total
volume and percentage of lung affected by fibrosis. Baseline pulmonary function test data
was correlated with the immediate post-transplant CT. Patients were followed for an average
of 35 months after transplant.
Results: The mean total volume of the native lung just after transplant was 1120 cc. This
decreased to 875 cc by 2 years and 691 cc by 4 years after transplant, representing an average
decline of 10.8%/year. Initially, 52% of the native lung was affected by fibrosis compared to 92%
at 4 years. Excluding scans with 100% of the lung affected by fibrosis, percentage fibrosis
increased 11% per year.
Conclusion: Fibrotic disease within the native lung progresses rapidly in single lung transplant
recipients with IPF despite prolonged high dose immunosuppression.
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Idiopathic pulmonary fibrosis (IPF) is a disease character-
ized by progressive lung fibrosis that is typically unrespon-
sive to traditional immunosuppressive agents such as
steroids.1 With an average 50% 3-year survival, patients
with IPF have a prognosis similar to lung cancer.2,3
Currently clinical trials are underway to determine the
effectiveness of alternative agents, however to date these
agents have demonstrated little effectiveness in arresting
the progression of fibrosis.4 The only long-term effective
treatment for IPF at this point is lung transplantation with
a 50% 5 year survival and with 26% of patients living to 10
years post-transplant.5
Single lung transplant recipients with idiopathic pulmo-
nary fibrosis (IPF) provide a unique opportunity to study
fibrosis in the native lung over time in the setting of
pronounced immunosuppression. At our institution, lung
transplant recipients are typically treated with a lifelong
regimen of steroids, an anti-proliferative agent (e.g.
mycophenolate mofetil) and a calcineurin inhibitor (e.g.
tacrolimus). To determine whether this combination of
immunosuppressive agents arrests the progression of
fibrosis, we performed a quantitative analysis of lung
volumes and severity of fibrosis on sequential high-resolu-
tion chest CT scans (HRCTs) of these patients following lung
transplantation. This paper is the first to perform direct
quantitative analysis of progression of fibrosis in this
patient population. The National Institutes of Health
‘‘Panther’’ trial plans to assess the efficacy of azathioprine,
predisone and N-acetylcysteine. The regimen in our
patients is arguably a greater degree of immunosupression
and would provide insight as to the likelihood of this trial
showing a treatment benefit in IPF patients.
Materials and methods
Patients
This single center study was approved by our institutional
review board and informed consent was waived. All
patients who underwent single lung transplantation for IPF
at our center between January 1996 and January 2006 were
included in the study. The diagnosis of IPF was made by the
criteria delineated by the American Thoracic Society and
European Respiratory Society.6 These criteria primarily
include a restrictive defect on pulmonary function tests,
typical HRCT findings (peripheral, basilar fibrosis with
honeycombing and a paucity of ground glass) and the
exclusion of other clinical disorders that could cause similar
fibrosis (e.g. collagen vascular disease, drugs, asbestosis).
The pathologic diagnosis of usual interstitial pneumonia
was confirmed in the explanted lung. Patients whose final
pathologic diagnosis was not consistent with IPF were
excluded from analysis. Pulmonary function testing was
performed in all patients within 3 months prior to lung
transplantation.
The post-transplant immunosuppression employed was
a standard three-drug regimen consisting of tacrolimus
(calcineurin inhibitor), mycophenolate mofetil (anti-
proliferative agent) and prednisone. The tacrolimus dailydose was based on serial follow-up of specific trough blood
levels; target levels were 10e14 ng/ml until three months
post-transplant at which point the target levels were low-
ered to 8e12 ng/ml. In addition, the specific dose in
a particular recipient is constantly being adjusted based on
drug interactions, recent rejection history and tacrolimus
adverse affects such as renal impairment among other
closely monitored factors. Mycophenolate mofetil was
initiated on the standard dose of 1000 mg bid with adjust-
ment for decrease in white blood cell count. The imme-
diate post-operative prednisone dose was 20 mg/day. Three
months post-transplant the dose was lowered to 15 mg/day
and following six months post surgery the dose was
adjusted to 0.2 mg/kg. The prednisone dose is also
constantly being adjusted for steroid related adverse
effects and rejection history.
CT technique
Following transplantation all patients underwent a HRCT
within 1e2 months, followed by repeat HRCTs at regular
intervals to evaluate for potential transplant complications
(e.g. infection, acute or chronic rejection). The scan
interval is variable between patients, but is typically at
least every 6 months. The severity of fibrosis in the native
lung was evaluated using these scans. The immediate post-
transplant HRCT was used as the patient’s baseline and
subsequent scans were evaluated at 6 month intervals.
HRCT scans were performed on either 16 or 64 detector
Lightspeed CT Scaners (GE Healthcare, Milwaukee, WI).
Three series were typically performed. Inspiratory images
were obtained in the supine position at 1 or 2 cm intervals
using a section thickness of 1.25 mm (2 detec-
tors 0.625 mm). The following parameters were used:
pitch 1.0, gantry rotation speed 400 ms, kVp 120 and
automatic mA adjustment. Prone and dynamic expiratory
images were also obtained, however these images were not
used for analysis. Images were analyzed on a Picture
Archiving and Communication System (PACS) workstation.
Image interpretation
Images were evaluated by two readers with subspecialty
training in pulmonary imaging. Two calculations were per-
formed in the native lung on each scan: total lung volume
and percentage of lung involved by fibrosis (Fig. 1). To
calculate the total native lung volume, the area of lung at
a specific level was calculated on the PACS workstation
using the ‘‘free-form region of interest’’ tool. This area was
calculated throughout the lung at 2 cm intervals. Subse-
quently, the total native lung volume was calculated by
summing the area at each level and multiplying by the
distance between each slice (2 cm). To calculate the
percentage of lung involved by fibrosis, the same method
was used except that only the regions affected by honey-
combing and reticulation were selected. These two findings
were chosen as they are most specific for fibrosis and are
the primary findings used to make a HRCT diagnosis of
IPF.7,8 Ground glass opacity, which also may be seen with
IPF, was not included in this measurement as it is a much
more non-specific finding and could represent fibrosis
Figure 1 Technique for calculating native lung area and % of fibrosis. Three images are shown, all at the same level. Area is
calculated at a specific level (B) by selecting the lung using the ‘‘free-form region of interest’’ tool. This is performed at 2 cm
intervals throughout the lung. These are summed and multiplied by 2 cm to calculate total lung volume. Calculation of the area of
lung fibrosis (C) is accomplished in the same manner except only selecting the regions of reticulation or honeycombing.
428 B.M. Elicker et al.below the resolution of CT or active inflammation.9 The
development of ground glass in the native lung was noted
by the readers, however, as ground glass opacity may be
seen in association with acute exacerbations of IPF. There
were three CT scans on which these calculations were
unable to be performed and were excluded because of
significant pleural effusions.
While this study focuses on abnormalities in the native
lung, significant abnormalities in the transplanted were
also noted. These were divided into two categories:
increased lung attenuation (nodules, ground glass opacity,
consolidation, airways inflammation) and decreased lung
attenuation (air trapping and mosaic perfusion). The
importance of this distinction is that the former most
commonly represent acute processes such as acute rejec-
tion or infection, whereas the later in this clinical setting
is typically due to chronic rejection/obliterative
bronchiolitis.
Statistical analysis
Statistical analysis was performed using SAS/STAT software
package version 9.1 (SAS Institute, Cary, NC) for Windows
(Microsoft, Redmond, WA). Correlations between the
baseline pulmonary function tests and the initial post-
transplant CT lung volumes and percentage of lung affected
by fibrosis were performed using the Spearman’s rank-order
correlation coefficients. Agreement between the two
readers in calculating the percentage of lung affected
fibrosis was performed using Pearson correlation
coefficients.
Statistical significance of decline in lung volumes over
time was performed using a mixed model regression. Since
measurements were taken on the same patients over time,
they are likely correlated. To accommodate this correla-
tion, mixed model regression was used. Unlike repeated
measures analysis of variance, mixed model regression also
allows for unbalanced data, use of all available data when
some are missing, and can incorporate predictors that
change from one time to the next. We fit a model allowingpatient specific intercepts and slopes since when looking at
plots of the individual patients’ lung volumes over time,
patients began with different lung volumes and their
progression over time appeared to have different rates.
Results
Twenty-one patients underwent single lung transplantation
at our center between January 1996 and January 2006 and
were included in this study. Patient demographics, in
addition to the pre-transplant IPF treatment regimen and
pre-transplant pulmonary function tests, are depicted in
Table 1. Patients were followed for an average of 35 months
after transplant (range 6 monthse90 months). The number
of patients included in analysis with respect to time after
transplant is as follows: immediately post-transplant (21), 1
year (20), 2 years (16), 3 years (12) and 4 years (5). Of these
patients, 12 died during the study period, 1 received an
additional lung, and 8 were alive at the end of the follow-
up period. The number of scans performed after the 4 year
post-transplant period was too small to be included in the
analysis.
Within the 4 year period after transplant a total of 136
CT scans were evaluated. Results are depicted in Table 2.
Progression of disease on HRCT in the native lung in two
representative patients is shown in Fig. 2.
Baseline pulmonary function testing, including diffusing
capacity of the lung for carbon monoxide (DLCO) and forced
vital capacity (FVC), was available on 20/21 patients prior
to lung transplant. There was a statistically significant
correlation between pre-transplant FVC and the native lung
volume calculated on the immediate post-transplant CT
(rZ 0.69, Spearman’s rank-order correlation; p< 0.001).
This is depicted in Fig. 3. Otherwise, no statistically
significant differences were seen between the PFT and CT
data.
The mean total native lung volume just after transplant
was 1120 cc (range 182e1994 cc). This declined to an
average of 875 cc by 2 years and 691 cc by 4 years. The
average yearly percentage decline in lung volume after
Table 1 Demographics of the 21 single lung transplant patients with IPF. The patients’ pre-transplant pulmonary function
tests are given including: forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO). The patients’
treatment for IPF prior to transplant is also included.
No Sex Race Age at transplant
(years)
FVC
(liters)
FVC
(% predicted)
DLCO
(mL/min/mmHg)
DLCO
(% predicted)
IPF treatment
prior to transplant
1 M Hispanic 54 1.9 50% 5.3 17% Prednisone
2 M Caucasian 46 2.55 52% 16.6 45% None
3 F Caucasian 59 1.69 57% 4.15 16% Prednisone,
gamma interferon
4 M Caucasian 56 1.9 44% 6.9 22% Gamma interferon
5 M Caucasian 54 2.4 51% 11.1 82% None
6 M Caucasian 59 3.3 68% 7.2 21% Prednisone, azathioprine
7 M African-American 54 2.28 54% 9.4 29% Prednisone, azathioprine
8 F Caucasian 41 1.9 6% 0.9 24% Gamma interferon,
mycophenolate mofetil
9 M Caucasian 67 1.3 31% 2.8 9% Prednisone, mycophenolate
mofetil
10 F Hispanic 62 1.4 60% 4.4 19% Azathioprine
11 M Caucasian 52 2.2 40% 8.9 57% None
12 F Caucasian 59 1.1 31% 2.9 29% Prednisone, azathioprine
13 M Caucasian 51 1.5 31% 8.8 77% None
14 M Caucasian 65 2.83 71% 6.4 22% None
15 M Caucasian 54 2.2 47% 7.7 49% Prednisone, azathioprine
16 M Caucasian 60 2.6 52% 8.6 24% Prednisone, azathioprine
17 F Hispanic 38 1.1 40% 4.3 36% Prednisone
18 M Caucasian 60 N/A N/A N/A N/A Gamma interferon
19 M Caucasian 47 2.9 55% 9.5 48% Cyclophosphamide
20 M Southeast Asian 63 2.34 60% 11.4 42% Gamma interferon
21 M Caucasian 65 1.54 48% 4.26 15% Azathioprine
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3rd year (10.4%) and 4th year (12.1%). On average the
native lung volume declined by 9.5 cc/month. Using mixed
model regression,10 this was a statistically significant
decline (95% CI: 12.67, 6.34, p< 0001). At the end of the
4 year period, the average patient had lost 29% of their
total lung volume when compared to baseline (Fig. 4).
Immediately after transplant, 52% (range 7e100%) of the
native lung was affected by fibrosis, compared to 65% at 2
years and 92% at 4 years. Excluding the 3 patients with
chest CT scans with 100% of the lung affected by fibrosis,
the average percentage of lung involved by fibrosis
increased 11% per year for the 4 year period after trans-
plant (Fig. 5). There was good agreement between the two
readers with regards to the volume of lung affected byTable 2 Average total lung volume and % of lung affected by fib
Years after transplant Lung volume (cc) % Volum
compare
0 1120 100%
0.5 1091 97%
1 1005 90%
1.5 976 87%
2 875 78%
2.5 724 65%
3 733 65%
3.5 748 67%
4 691 62%fibrosis using Pearson’s correlation coefficient (rZ 0.9131,
p< 0.001).
All but five patients showed an overall 10% decrease in
total lung volume during the study period. Of the five
patients who showed <10% decrease in total lung volume
one already had 100% of the lung affected by fibrosis, one
had only 6 months of follow-up, and the other three showed
an average increase of percent fibrosis of 31% over the 4
year post-transplant period.
Three patients had a native lung which was 100%
affected by fibrosis and had CT follow-up for greater than
12 months. These patients showed an average decrease in
total lung volume of 5.4%/year.
Abnormalities within the transplanted lung that showed
increased attenuation, excluding mild scarring or atelectasis,rosis in the native lung over time after single lung transplant.
e
d to baseline
% Lung
affected by fibrosis
# Patients
52% 21
52% 21
59% 20
62% 18
65% 16
72% 13
78% 12
76% 10
92% 5
Figure 2 Progression of native lung fibrosis over time in 2 different IPF patients status post unilateral lung transplant. Over the
4e5 year intervals depicted in these patients there were significant decreases in lung volume and increase in percentage of lung
affected by fibrosis.
430 B.M. Elicker et al.were seenona total of 24 of 136CTscans.Theseabnormalities
included the following: ground glass opacity (15), consolida-
tion (4), extensive scarring (2), airways inflammation (2) and
interlobular septal thickening (1). These abnormalities also
involvedthenative lung inonly twocases. Inoneof thesecases
the ground glass subsequently resolved, but in the other itwas
persistent and eventually evolved to fibrosis. It is possible this
represented an acute exacerbation of IPF.
Mosaic perfusion and/or air trapping were seen on
a total of 81 of 136 CT scans. This was classified as mild on
62 CTs, moderate on 14 CTs and severe on 5 CTs.Discussion
IPF is a devastating disease with a very poor prognosis.
Pharmacologic treatment of IPF has been largely ineffec-
tive and many clinical trials have been hampered by poor
study design, making positive results of uncertain signifi-
cance.11 Traditional immunosuppression with steroids does
not slow the progression of disease or incidence of acute
exacerbations in the majority of patients.1 Recent clinical
trials have focused on immunomodulatory agents such as
Interferon g-1b12 and Pirfenidone.13 In general, the use of
these agents has shown only limited effectiveness in slow-
ing the progression of IPF in specific patient subgroups.14
Single lung transplant patients with IPF at our institution
are treated with a lifelong regimen of steroids, an anti-
proliferative agent (e.g. mycophenolate mofetil) and
a calcineurin inhibitor (e.g. tacrolimus). The combination
of these agents represents a significantly greater degree of
immunosuppression than average treatment for non-trans-
planted patients with IPF. The primary goal of this study
was to evaluate the ability of this combination of medica-
tions to arrest the progression of disease within the nativelung. While mycophenolate has been suggested as
a possible treatment for IPF,15 to date there have been no
clinical trials performed to assess the usefulness of either
this drug or calcinuerin inhibitors in the treatment of IPF.
There is one study which investigates the use of tacrolimus
in attenuating drug induced fibrosis in a mouse model.16
In our study, the combination of medications used for
lung transplant patients showed no ability to arrest the
progression of fibrosis. There was a continued decline in
lung volumes of 10.8%/year and increase in the percentage
of lung affected by fibrosis of 11%/year for the four year
period after transplant. There is little data quantifying the
sequential progression of disease in patients with IPF prior
to transplant. Most information has come out of short term
follow-up in clinical trials. For instance, average decline
of forced vital capacity over a 12 month period in the
recent Bosentan trial ranged from 6.4 to 7.7%.17 In
a recent pirfenidone trial the decline in vital capacity over
a 9 month period ranged from 0.03 to 0.13 L.13 In our study
the total native lung volume showed an average decline of
0.1 L/year for the first 4 years after transplant.
Virtually all patients showed either a decrease in native
lung volume or an increase in the percentage of native lung
affected by fibrosis in this study. There were two excep-
tions, one of which already had 100% of the lung affected
by fibrosis and the other of which had only 6 months of
follow-up. Thus, the combination of immunosuppressive
agents used in this study did not arrest or even slow the
progression of disease in the native lung over time.
To our knowledge, this is the first study to perform direct
quantitative analysis of lung volumes and percentage of
lung affected by fibrosis in single lung transplant patients
with IPF over time. Two other studies have evaluated
progression of lung fibrosis after transplant.18,19 Our study
involves a larger population group (21 vs. 5 and 13 patients
Figure 3 Forced vital capacity on PFTs immediately prior to transplant compared to total native lung volume calculated on CT
immediately after transplant. Note that the FVC includes both lungs, however the total lung volume CT calculation is only for the
one remaining lung. Trendline using linear regression analysis is shown.
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volumes and percentage of lung affected by fibrosis as
opposed to using semi-quantitative measurements. The
semi-quantitative method likely provides a less precise
measurement of disease and is difficult to interpret in the
context of pulmonary function measurements. While labor
intensive, these quantitative measurements may in the
near future may be very easy to calculate using automated
computerized models, currently under development.20
Additionally, the patients in the study by Grigic et al.
received a cyclosporine-based regimen, whereas our
patients were given the combination of an anti-prolifera-
tive agent and a calcineurin inhibitor. Our regimen arguably
represents a greater degree of immunosuppression.
A few other studies have evaluated changes on serial CTs
of non-transplanted IPF patients21e23 who were either not
treated with immunosuppressive agents or who were
treated with traditional IPF agents. All have shown
progression of CT findings in both groups.
There are several other interesting observations in this
study. First, the lung volume and percentage of lung
affected by fibrosis are widely variant in patients who have
just been transplanted. The lung volumes range from 182 toFigure 4 Plot of average volume of the native lung over time afte
provided.1994 cc and the percentage of lung affected by fibrosis
ranges from 7 to 100%. This strongly suggests that the
severity of fibrosis does not necessarily correlate with the
need for transplant and that other significant factors
contribute to a worsening clinical status. Pulmonary arte-
rial hypertension is likely a significant contributor and does
not always correlate with the severity of lung fibrosis either
on CT24 or as calculated on PFTs.25 While hypoxic reflex
vasoconstriction and perivascular fibrosis are significant
contributors to pulmonary hypertension in chronic fibrotic
lung diseases, other etiologies such as vascular inflamma-
tion and thrombosis also have been suggested to play
a role.26 This would explain discrepancies between severity
of fibrosis and need for transplant.
The natural history of disease in the native lung beyond
the point at which the patient would typically survive is not
known. It is interesting to note that fibrosis in the native
lung continues to progress at a rapid rate even with severe
baseline disease. Lung volumes decrease even in some
patient’s whose lungs are entirely affected by fibrosis,
suggesting worsening of the fibrosis on a microscopic level.
Understanding the natural progression of disease within the
native lung will also serve to prevent misinterpretation ofr single lung transplant. Standard error of measurement bars is
Figure 5 Plot of percentage of native lung affected by fibrosis over time after single lung transplant. Standard error of
measurement bars is provided.
432 B.M. Elicker et al.CT scan changes over time. As findings in fibrotic lung are
characteristically difficult to interpret, progression of
fibrosis should not be mistaken for infection or other enti-
ties that may produce increased lung opacity.
To our knowledge, there has been only one patient in our
lung transplant practice that has been diagnosed with an
acute exacerbation of IPF after single lung transplant. This
patient was not transplanted during the study period. Upon
review of the CT scans of the patients included in this
analysis, one patient was identified with acute ground glass
in the native lung which persisted and subsequently pro-
gressed to fibrosis. It is possible that this also represented
an acute exacerbation. As acute exacerbations predomi-
nantly involve the fibrotic lung, it is rare to obtain definitive
proof of disease in transplanted patients. Also, the inci-
dence of acute exacerbation of IPF in the non-transplant
IPF population is not clearly defined. Thus, we cannot make
any conclusions about the ability of our immunosuppressive
regime to decrease the incidence of acute exacerbation. It
is interesting to note, however, that the ground glass
opacity in this patient also affected the transplanted lung,
albeit to a much lesser extent. It is possible that an acute
exacerbation of IPF in single lung transplant could have
some negative effects on not only the native lung, but the
transplanted lung as well.
There are several potential limitations to this study. The
HRCT technique, which only provides a sampling of the lung
allows for slight inconsistencies from scan to scan. Validity
of the calculation of lung volumes and percentage of lung
affected by fibrosis assumes a relative homogeneity of
disease between images taken at selected levels. While this
may lead to slight inconsistencies over the short term,
there was convincing long-term decrease in volume and
increase in percentage of fibrotic lung over multiple follow-
up scans. Another limitation is the relatively small number
of patients included in analysis at the 4 year point (5). This
is inevitable as the average national 3 year survival of lung
transplant patients is approximately 60%.
In conclusion, the native lung in transplant patients with
IPF continues to show a decrease in total lung volume and
increase in the percentage of lung affected by fibrosis over
time. This occurs despite a combination of potent immu-
nosuppressive agents. It is known that steroids do not likelyarrest the progression of disease in IPF. The other agents
used in lung transplant patients, anti-proliferative agents
(e.g. mycophenolate mofetil) and a calcineurin inhibitor
(e.g. tacrolimus), also do not appear to arrest the
progression of disease in IPF patients. These results have
significant implications for future clinical trials involving
these agents.
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